Failure of Omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy

被引：0
|
作者：
Gomis, V. Soriano [1 ]
Delgado, P. Gonzalez [1 ]
Hernandez, E. Niveiro [1 ]
机构：
[1] Gen Hosp Univ Alicante, Secc Alergia, Alicante 0310, Spain
来源：
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY | 2008年 / 18卷 / 03期
关键词：
immunotherapy; omalizumab; anaphylactic reaction; bee venom;
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：225 / 226
页数：2
相关论文
共 38 条
  • [31] Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report
    Gervais, C.
    Auclin, E.
    Saltel-Fulero, A.
    Clair, G.
    Oudard, S.
    Mirghani, H.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (04) : 231 - 234
  • [32] Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma
    Pestana, Roberto Carmagnani
    Becnel, Melody
    Rubin, Maria Laura
    Torman, Danice K.
    Crespo, James
    Phan, Jack
    Hanna, Ehab
    Bell, Diana
    Glisson, Bonnie S.
    Johnson, Jason M.
    Lee, J. Jack
    Ferrarotto, Renata
    ORAL ONCOLOGY, 2020, 101
  • [33] The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
    Yu, Shengsheng
    Smith, Alex
    Hass, Steve
    Wu, Eric
    Chai, Xinglei
    Zhou, Jenny
    Ayyagari, Rajeev
    Liu, Jun S.
    Robison, Dan
    Donelson, Sarah M.
    Tilles, Stephen
    ADVANCES IN THERAPY, 2021, 38 (08) : 4321 - 4332
  • [34] The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
    Shengsheng Yu
    Alex Smith
    Steve Hass
    Eric Wu
    Xinglei Chai
    Jenny Zhou
    Rajeev Ayyagari
    Jun S. Liu
    Dan Robison
    Sarah M. Donelson
    Stephen Tilles
    Advances in Therapy, 2021, 38 : 4321 - 4332
  • [35] Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
    Chen, Shubin
    Yu, Qitao
    Jiang, Wei
    Lu, Yukun
    Zhao, Yun
    Wang, Huilin
    FRONTIERS IN MEDICINE, 2023, 10
  • [36] Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials
    Wang, Kang
    Fu, Zhenxue
    Sun, Guanxing
    Ran, Yancui
    Lv, Nannan
    Wang, Enbo
    Ding, Huan
    BMC IMMUNOLOGY, 2024, 25 (01)
  • [37] Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy:: a phase II trial
    Ravaud, A
    Trufflandier, N
    Ferrière, JM
    Debled, M
    Palussière, J
    Cany, L
    Gaston, R
    Mathoulin-Pélissier, S
    Bui, BN
    BRITISH JOURNAL OF CANCER, 2003, 89 (12) : 2213 - 2218
  • [38] Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial
    A Ravaud
    N Trufflandier
    J M Ferrière
    M Debled
    J Palussière
    L Cany
    R Gaston
    S Mathoulin-Pélissier
    B N Bui
    British Journal of Cancer, 2003, 89 : 2213 - 2218
1234